medicines transparency alliance13/09/2015 1 meta uganda country overview public sector private...
Post on 27-Dec-2015
248 Views
Preview:
TRANSCRIPT
Medicines Transparency Alliance19/04/23 1
MeTA Uganda
Country OverviewPublic SectorPrivate SectorCivil Society
Medicines Transparency Alliance19/04/23 3
Multi-stakeholder process
Milestones:
Multi-stakeholder collaboration: first time in the pharmaceutical sector
Capacity building and formation of an umbrella organization for CSOs
Participation of private sector and CSOs in the development of the NPSSP II
Amendment of the counterfeit goods bill: a CSO-led process in which NDA and private sector were invited
Input of MeTA Council was crucial to success of the “STOP STOCK OUT” campaign
Medicines Transparency Alliance
Major achievements and successes
NDA database of registered drugs is now searchable online www.nda.or.ug
Improved intra-government efficiency as NDA verification information will be available to MoH
Improved access to information by the private sector e.g. MoH procurement plan, medicines price monitor
Increased public debate and reporting on medicines-related issues such as stock outs
Resolutions from the forum on NMS/JMS/NDA improving efficiencies re sharing information on quality assurance data
19/04/23 4
Medicines Transparency Alliance
Overall challenges
Slow start
Variable participation in the process (competing priorities, no direct incentives)
High member expectations of funding esp. CSOs
Disclosure is still a challenge, still in the process of making an inventory, modalities unclear
Insufficient visibility for MeTA (esp. in MoH structures)
Dissemination of available information from stakeholders is still not effective
19/04/23 5
Medicines Transparency Alliance
Overall challenges 2
The need for “Patience” in working as a multi-sector team!
Acceptance that the different sectors work in different ways, e.g. Private sector appears to have more sense of urgency - deadline driven!
Involve the “full” private sector in the discussions and get commitment for actions
19/04/23 6
Medicines Transparency Alliance
Lessons Learned
It takes time for such initiatives to take off: pilot phase too short to expect meaningful results
The disclosure survey unleashed gaps in pharmaceutical sector which MeTA is working to prioritize
Better planning needful at onset of initiative to prevent delays in take off, ownership of activities.
19/04/23 7
Medicines Transparency Alliance19/04/23 9
Thank you
Jacqueline Idusso Email: jackie.idusso@gmail.com
Mobile number: +256-752-656380
Skype: metauganda
Website: www.MedicinesTransparency.org
Medicines Transparency Alliance19/04/23 10
Public Sector
Presenter: Oteba Olowo MartinJob Title: Assistant Commissioner health
Services (pharmacy)
Medicines Transparency Alliance19/04/23 11
Multi-stakeholder process - milestones
Establishment of the MeTA country chapter with a secretariat facilitated by a national coordinator
CSO – Government – Private sector multistakeholder national MeTA council established
the National Pharmaceutical Sector Strategic Plan (NPSSP) supported – draft NPSSP produced
Facilitating transparency in the medicines registration process – register of medicines regularly updated and accessible on website free of charge
Medicines Transparency Alliance
Multi-stakeholder process - milestones
The three year procurement plan evaluated, updated and shared among stakeholders in the health sector
19/04/23 12
Medicines Transparency Alliance
Major achievements and successes – MeTA Uganda
Joint action in areas hitherto of mutual suspicion achieved
Understanding diversity, taking advantage of the opportunities therein for collective and effective policy development and implementation
Medicines price monitoring conducted on a quarterly basis
Process of computerizing medicines import data started and dialogue for continued support by other partners initiated
The NPSSP reviewed through a wider stakeholder process – Document available in draft form (Yet to be costed)
19/04/23 13
Medicines Transparency Alliance
Overall challenges during the pilot – MeTa Uganda
Appreciating the MeTA core values and value add to the various stakeholders
Breaking barriers between stakeholders and opening up opportunities for synergistic actions – time waste
Building trust and confidence among the stakeholders
Time waste in addressing the individual stakeholder interests and concerns
\Most project outcomes yet to be evaluated for broader impact
19/04/23 14
Medicines Transparency Alliance
Lessons Learned – MeTA Uganda
Soliciting goodwill and support by stakeholders should not be taken for granted
Stakeholder prior understanding of new initiatives provides good grounds for buy in
The pilot phase as a consequence of the lag phase has been ultimately shorter than was expected creating pressure in the implementation of agreed on programmes at country
Stakeholder engagement provides requisite grounds for mitigating and or eliminating potential conflict and allows for progressive synergy in moving forward agenda in medicines transparency programmes
19/04/23 15
Medicines Transparency Alliance
Lessons Learnt
Understanding each others interests, mandates and responsibilities and positively sharing the concerns of the other parties.
19/04/23 16
Medicines Transparency Alliance19/04/23 17
Thank you
Name of presenter: Oteba Olowo Martin Email: orukan33@hotmail.com
Mobile number: +256 772 512 975
Skype:
Website:
Medicines Transparency Alliance19/04/23 18
Private Sector
Nazeem MohamedC.E.O. Kampala Pharmaceutical Industries (1996) Ltd
Medicines Transparency Alliance19/04/23 19
Summary Analysis at start of MeTA
Issues– Market dominated by subsidised imports from India and China
• Prices are cheap,
• Huge variability in stocks
• Subsidised imports impact on competitiveness of local manufacturers
– Perceived lack of clear policies to support local manufacturing
– Lack of adequate Government support for local manufacturing
Medicines Transparency Alliance
Issues 2
– Relatively strong regulations and enforcement in place
– Increasing commercialization of health care provision
– Weak infrastructure which increases the cost of distribution and availability of essential drugs.
– Poor and inadequate patient and customer service
– Lack of knowledge and dissemination of patient rights – Wide spread corruption in areas of health service delivery, procurement,
leakage of products etc...
– No point of reference to access data on pricing, margins, or availability of essential drugs
19/04/23 20
Medicines Transparency Alliance
Major milestones
Private sector has been provided a seat on the table!!
Private sector recognized as a significant and growing player in health care service delivery
Opportunities created for dialogue with the Government, CSO’s and development partners
19/04/23 21
Medicines Transparency Alliance
Successes
Invited to participate in development of Government’s Pharmaceutical Strategic Plan (NPSSP) for 2010-2015
Worked with CSO’s on “Counterfeit Bill” and submitted a common position to the Government
Initiated discussion with Academia to improve technical skill base among graduates and company staff
Initiation of a project to promote the value of “generics” and local manufacturing
Identified need to collect and disseminate data on the market, e.g. Importation, use of different medicines, trends in usage, etc
19/04/23 22
Medicines Transparency Alliance
Challenges
The need for “patience for results” in working as part of a multi-sector team!
Understanding that sectors have varying objectives and work in different ways, e.g. private sector tends to act with more sense of urgency
Involving the “full breadth/spectrum” of private sector in the discussions and getting commitment for actions
Lack of empirical information on characteristics, extent, growth and consequences of unregulated commercial health care provision
19/04/23 23
Medicines Transparency Alliance
Lessons Learned
Most issues of concern are common to different stakeholder groups
Understanding and appreciating the role each sector can play in making multi stakeholder initiatives/processes work
Identifying and involving all stakeholders that will contribute to the success of the multi stakeholder process
The role of advocacy/lobbying in ensuring that private sector concerns are considered during policy formulation
The need for strengthening the capacity of government to constructively engage the private sector
Building trust and constructive policy dialogue are vital for successful engagement
19/04/23 24
Medicines Transparency Alliance19/04/23 26
Summary Analysis at start of MeTA
What were the needs and issues in your specific sector at the start of MeTA?
Access to medicines:- Availability of medicines; Medicine prices; Monitoring and accountability; Rational use
Create public awareness; increase transparency in medicine supply chain (policy and practice), roles of key medicine sector institutions (NDA,NMS etc)
CSO coordination and communication
Capacity building of CSOs for effective participation in medicine sector
Representation of CSOs on the different decision making structures
Medicines Transparency Alliance
Major milestones
What milestones have been achieved during the MeTA pilot phase?
Two CSOs HEPS and Uganda National Health Consumers Organization (UNHCO) were selected to sit on MeTA Council
Rosette Mutambi (Executive Director HEPS) was chosen as first rotating Co-Chair of MeTA Uganda Council.
At inception of MeTA in early 2008, HEPS was chosen to present CSOs on Ministry of Health Technical Working Group on Medicines Procurement and Management
CSOs empowered to meaningfully participate in the planned multi-stakeholder activities in Uganda and feel more comfortable to engage with national policy processes
MeTA has provided CSOs with access to government bodies
Work plan on track
19/04/23 27
Medicines Transparency Alliance
Successes
What were the successes for your sector during the MeTA pilot phase?
For the first time ever, the Ministry of Health invited CSOs to the National Pharmaceutical Sector Strategizing Workshop in July/ August 2009
Increased public debate and reporting on medicine issues for example stock outs
Increased collaboration between government bodies, private sector to improve access to medicine
MeTA council provided useful input into materials used for the Stop Stock outs campaign
Shared responsibility among CSOs in implementing work plan
19/04/23 28
Medicines Transparency Alliance
Challenges
What challenges has your sector endured during the MeTA pilot phase?
Constant communication which is required to maintain interest and to keep members updated on MeTA issues is a challenge
High member expectations of funding
District CBOs not yet aware of MeTA
Increased pressure from public to CSOs to demand/cause change
19/04/23 29
Medicines Transparency Alliance
Lessons Learned
What are the lessons that your sector has learned from MeTA?
There is shared responsibility by all stakeholders to increase access to medicines and all sectors have a contribution
MSP helps sectors to understand role of others and their key competencies in improving access to medicines
MSP important in increasing transparency and accountability
An enlightened Civil Society is crucial to advocacy
19/04/23 30
Medicines Transparency Alliance19/04/23 31
Capacity Building Workshop
CSO participants of Capacity Building Workshop
top related